PTPN11 and acute myeloid leukemia: Activating mutations in SHP2 have been well characterized as oncogenic drivers in hematologic malignancies, including juvenile myelomonocytic leukemia (JMML) and subsets of acute myeloid leukemia (AML), and as germline mutations which underlie Noonan syndrome (NS)16.